Springer Science and Business Media LLC

Công bố khoa học tiêu biểu

* Dữ liệu chỉ mang tính chất tham khảo

Sắp xếp:  
Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus
Springer Science and Business Media LLC - Tập 21 - Trang 1-9 - 2022
Yuta Suzuki, Hidehiro Kaneko, Akira Okada, Hidetaka Itoh, Satoshi Matsuoka, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Kentaro Kamiya, Atsuhiko Matsunaga, Junya Ako, Koichi Node, Hideo Yasunaga, Issei Komuro
There have been scarce data comparing cardiovascular outcomes between individual sodium-glucose cotransporter-2 (SGLT2) inhibitors. We aimed to compare the subsequent cardiovascular risk between individual SGLT2 inhibitors. We analyzed 25,315 patients with diabetes mellitus (DM) newly taking SGLT2 inhibitors (empagliflozin: 5302, dapagliflozin: 4681, canagliflozin: 4411, other SGLT2 inhibitors: 10,921). We compared the risks of developing heart failure (HF), myocardial infarction (MI), angina pectoris (AP), stroke, and atrial fibrillation (AF) between individual SGLT2 inhibitors. Median age was 52 years, and 82.5% were men. The median fasting plasma glucose and HbA1c levels were 149 (Q1-Q3:127–182) mg/dL and 7.5 (Q1-Q3:6.9–8.6) %. During a mean follow-up of 814 ± 591 days, 855 HF, 143 MI, 815 AP, 340 stroke, and 139 AF events were recorded. Compared with empagliflozin, the risk of developing HF, MI, AP, stroke, and AF was not significantly different in dapagliflozin, canagliflozin, and other SGLT inhibitors. For developing HF, compared with empagliflozin, hazard ratios of dapagliflozin, canagliflozin, and other SGLT2 inhibitors were 1.02 (95% confidence interval [CI] 0.81–1.27), 1.08 (95% CI 0.87–1.35), and 0.88 (95% CI 0.73–1.07), respectively. Wald tests showed that there was no significant difference in the risk of developing HF, MI, AP, stroke, and AF among individual SGLT2 inhibitors. We confirmed the robustness of these results through a multitude of sensitivity analyses. The risks for subsequent development of HF, MI, AP, stroke, and AF were comparable between individual SGLT2 inhibitors. This is the first study comparing the wide-range cardiovascular outcomes of patients with DM treated with individual SGLT2 inhibitors using large-scale real-world data.
Huyết áp và tỷ lệ tử vong ở bệnh nhân tiểu đường loại 2 có sự kiện tim mạch gần đây trong thử nghiệm ELIXA Dịch bởi AI
Springer Science and Business Media LLC - Tập 19 - Trang 1-11 - 2020
Magnus O. Wijkman, Brian Claggett, Rafael Diaz, Hertzel C. Gerstein, Lars Køber, Eldrin Lewis, Aldo P. Maggioni, Emil Wolsk, David Aguilar, Rhonda Bentley-Lewis, John J. McMurray, Jeffrey Probstfield, Matthew Riddle, Jean-Claude Tardif, Scott D. Solomon, Marc A. Pfeffer
Mối quan hệ giữa huyết áp và tỷ lệ tử vong ở bệnh tiểu đường loại 2 (T2DM) là một vấn đề gây tranh cãi, với lo ngại về nguy cơ gia tăng liên quan đến huyết áp giảm quá mức. Chúng tôi đánh giá liệu bệnh tim mạch trước đó (CVD) có làm thay đổi mối quan hệ giữa huyết áp ban đầu và tỷ lệ tử vong do mọi nguyên nhân ở 5852 bệnh nhân T2DM có hội chứng vành cấp tính gần đây (ACS) tham gia thử nghiệm ELIXA (Đánh giá Lixisenatide trong Hội chứng vành cấp tính) hay không. Nguy cơ tử vong được đánh giá trong các mô hình Cox đã điều chỉnh cho tuổi, giới tính, chủng tộc, nhịp tim, chỉ số khối cơ thể (BMI), thời gian mắc tiểu đường, sử dụng insulin, HbA1c, eGFR, peptide natri lợi niệu não (BNP), tỷ lệ albumin/creatinine trong nước tiểu, phân bố điều trị và tái thông mạch vành trước đó. Mặc dù không có mối liên hệ đáng kể nào giữa huyết áp tâm thu (SBP) và tỷ lệ tử vong (tỷ lệ nguy cơ cho mỗi 10 mmHg huyết áp tâm thu giảm 1,05 (95% CI 0,99–1,12) P = 0,10), huyết áp tâm thu thấp hơn có liên quan đáng kể với nguy cơ tử vong cao hơn (tỷ lệ nguy cơ cho mỗi 10 mmHg huyết áp tâm thu giảm 1,13 (95% CI 1,04–1,22) P = 0,002) ở 2325 bệnh nhân có CVD bổ sung (ACS chỉ số + ít nhất một trong các yếu tố sau trước khi phân tầng: nhồi máu cơ tim khác ngoài ACS chỉ số, đột quỵ hoặc suy tim). Ở 3527 bệnh nhân chỉ có ACS chỉ số không quan sát thấy mối liên hệ đáng kể nào (tỷ lệ nguy cơ cho mỗi 10 mmHg huyết áp tâm thu giảm 0,95 (0,86–1,04) P = 0,26; P cho tương tác 0,005). Mối liên hệ giữa huyết áp và tỷ lệ tử vong bị thay đổi bởi lịch sử CVD bổ sung ở những bệnh nhân tiểu đường loại 2 và sự kiện mạch vành gần đây. Khi sử dụng huyết áp được đo sau một sự kiện vành cấp tính để đánh giá nguy cơ tử vong ở bệnh nhân tiểu đường loại 2, cần xem xét lịch sử tim mạch. Đăng ký thử nghiệm số ClinicalTrials.gov NCT01147250, lần đầu tiên được đăng vào ngày 22 tháng 6 năm 2010
Ciprofibrate therapy in patients with hypertriglyceridemia and low high density lipoprotein (HDL)-cholesterol: greater reduction of non-HDL cholesterol in subjects with excess body weight (The CIPROAMLAT study)
Springer Science and Business Media LLC - Tập 3 - Trang 1-6 - 2004
Carlos A Aguilar-Salinas, Andréia Assis-Luores-Vale, Benjamín Stockins, Hector Mario Rengifo, José Dondici Filho, Abrahão Afiune Neto, Lísia Marcílio Rabelo, Kerginaldo Paulo Torres, José Egídio Paulo de Oliveira, Carlos Alberto Machado, Eliana Reyes, Victor Saavedra, Fernando Florenzano, Ma Victoria Hernández, Sergio Hernandez Jiménez, Erika Ramírez, Cuauhtémoc Vazquez, Saul Salinas, Ismael Hernández, Octavio Medel, Ricardo Moreno, Paula Lugo, Ricardo Alvarado, Roopa Mehta, Victor Gutierrez, Francisco J Gómez Pérez
Hypertriglyceridemia in combination with low HDL cholesterol levels is a risk factor for cardiovascular disease. Our objective was to evaluate the efficacy of ciprofibrate for the treatment of this form of dyslipidemia and to identify factors associated with better treatment response. Multicenter, international, open-label study. Four hundred and thirty seven patients were included. The plasma lipid levels at inclusion were fasting triglyceride concentrations between 1.6–3.9 mM/l and HDL cholesterol ≤ 1.05 mM/l for women and ≤ 0.9 mM/l for men. The LDL cholesterol was below 4.2 mM/l. All patients received ciprofibrate 100 mg/d. Efficacy and safety parameters were assessed at baseline and at the end of the treatment. The primary efficacy parameter of the study was percentage change in triglycerides from baseline. After 4 months, plasma triglyceride concentrations were decreased by 44% (p < 0.001). HDL cholesterol concentrations were increased by 10% (p < 0.001). Non-HDL cholesterol was decreased by 19%. A greater HDL cholesterol response was observed in lean patients (body mass index < 25 kg/m2) compared to the rest of the population (8.2 vs 19.7%, p < 0.001). In contrast, cases with excess body weight had a larger decrease in non-HDL cholesterol levels (-20.8 vs -10.8%, p < 0.001). There were no significant complications resulting from treatment with ciprofibrate. Ciprofibrate is efficacious for the correction of hypertriglyceridemia / low HDL cholesterol. A greater decrease in non-HDL cholesterol was found among cases with excess body weight. The mechanism of action of ciprofibrate may be influenced by the pathophysiology of the disorder being treated.
CCL7 as a novel inflammatory mediator in cardiovascular disease, diabetes mellitus, and kidney disease
Springer Science and Business Media LLC -
Ting‐Ting Chang, Ching Chen, Jaw-Wen Chen
Abstract

Chemokines are key components in the pathology of chronic diseases. Chemokine CC motif ligand 7 (CCL7) is believed to be associated with cardiovascular disease, diabetes mellitus, and kidney disease. CCL7 may play a role in inflammatory events by attracting macrophages and monocytes to further amplify inflammatory processes and contribute to disease progression. However, CCL7-specific pathological signaling pathways need to be further confirmed in these chronic diseases. Given the multiple redundancy system among chemokines and their receptors, further experimental and clinical studies are needed to clarify whether direct CCL7 inhibition mechanisms could be a promising therapeutic approach to attenuating the development of cardiovascular disease, diabetes mellitus, and kidney disease.

Low circulating pentraxin 3 levels in pregnancy is associated with gestational diabetes and increased apoB/apoA ratio: a 5-year follow-up study
Springer Science and Business Media LLC - - 2016
Tove Lekva, Annika Elisabeth Michelsen, Jens Bollerslev, Errol R. Norwitz, Pål Aukrust, Tore Henriksen, Thor Ueland
Gestational diabetes mellitus (GDM) is a significant risk factor for cardiovascular disease (CVD) in later life. Pentraxin 3 (PTX3) is an essential component of innate immunity and independently associated with the risk of developing vascular events. The aim of the study was to examine the relationships between GDM, cardiovascular risk, and plasma PTX3 in pregnancy and at 5 years after the index pregnancy. This population-based prospective cohort included 300 women who had an oral glucose tolerance test (OGTT) during pregnancy. Five years later, the OGTT was repeated along with dual-energy x-ray absorptiometry, lipid analysis, and pulse wave velocity analysis. Fasting PTX3 levels were measured four times during pregnancy and at follow-up. PTX3 levels were lower early in pregnancy and at 5 years follow-up in women who developed GDM. PTX3 levels throughout pregnancy were associated with body mass index. Low PTX3 levels in early pregnancy were predictive of an increased apoB/apoA ratio at 5-year follow-up. PTX3 at 5-year follow-up was inversely correlated with multiple metabolic risk factors for CVD, including body composition, arterial stiffness, dyslipidemia and previous GDM. Our results show that low plasma concentration of PTX3 in early pregnancy is associated with subsequent development of GDM and with an enhanced risk for CVD as estimated by an elevated apoB/apoA ratio at 5 years postpartum.
Evaluating the impact of glucokinase activation on risk of cardiovascular disease: a Mendelian randomisation analysis
Springer Science and Business Media LLC - Tập 21 - Trang 1-10 - 2022
Ke Wang, Mai Shi, Chuiguo Huang, Baoqi Fan, Andrea O. Y. Luk, Alice P. S. Kong, Ronald C. W. Ma, Juliana C. N. Chan, Elaine Chow
Glucokinase activators (GKAs) are an emerging class of glucose lowering drugs that activate the glucose-sensing enzyme glucokinase (GK). Pending formal cardiovascular outcome trials, we applied two-sample Mendelian randomisation (MR) to investigate the impact of GK activation on risk of cardiovascular diseases. We used independent genetic variants in or around the glucokinase gene meanwhile associated with HbA1c at genome-wide significance (P < 5 × 10−8) in the Meta-Analyses of Glucose and Insulin-related traits Consortium study (N = 146,806; European ancestry) as instrumental variables (IVs) to mimic the effects of GK activation. We assessed the association between genetically proxied GK activation and the risk of coronary artery disease (CAD; 122,733 cases and 424,528 controls), peripheral arterial disease (PAD; 7098 cases and 206,541 controls), stroke (40,585 cases and 406,111 controls) and heart failure (HF; 47,309 cases and 930,014 controls), using genome-wide association study summary statistics of these outcomes in Europeans. We compared the effect estimates of genetically proxied GK activation with estimates of genetically proxied lower HbA1c on the same outcomes. We repeated our MR analyses in East Asians as validation. Genetically proxied GK activation was associated with reduced risk of CAD (OR 0.38 per 1% lower HbA1c, 95% CI 0.29–0.51, P = 8.77 × 10−11) and HF (OR 0.54 per 1% lower HbA1c, 95% CI 0.41–0.73, P = 3.55 × 10−5). The genetically proxied protective effects of GKA on CAD and HF exceeded those due to non-targeted HbA1c lowering. There was no causal relationship between genetically proxied GK activation and risk of PAD or stroke. The estimates in sensitivity analyses and in East Asians were generally consistent. GKAs may protect against CAD and HF which needs confirmation by long-term clinical trials.
Cardiac metabolism in a new rat model of type 2 diabetes using high-fat diet with low dose streptozotocin
Springer Science and Business Media LLC - Tập 12 - Trang 1-10 - 2013
Latt S Mansor, Eileen R Gonzalez, Mark A Cole, Damian J Tyler, Jessica H Beeson, Kieran Clarke, Carolyn A Carr, Lisa C Heather
To study the pathogenesis of diabetic cardiomyopathy, reliable animal models of type 2 diabetes are required. Physiologically relevant rodent models are needed, which not only replicate the human pathology but also mimic the disease process. Here we characterised cardiac metabolic abnormalities, and investigated the optimal experimental approach for inducing disease, in a new model of type 2 diabetes. Male Wistar rats were fed a high-fat diet for three weeks, with a single intraperitoneal injection of low dose streptozotocin (STZ) after fourteen days at 15, 20, 25 or 30 mg/kg body weight. Compared with chow-fed or high-fat diet fed control rats, a high-fat diet in combination with doses of 15–25 mg/kg STZ did not change insulin concentrations and rats maintained body weight. In contrast, 30 mg/kg STZ induced hypoinsulinaemia, hyperketonaemia and weight loss. There was a dose-dependent increase in blood glucose and plasma lipids with increasing concentrations of STZ. Cardiac and hepatic triglycerides were increased by all doses of STZ, in contrast, cardiac glycogen concentrations increased in a dose-dependent manner with increasing STZ concentrations. Cardiac glucose transporter 4 protein levels were decreased, whereas fatty acid metabolism-regulated proteins, including uncoupling protein 3 and pyruvate dehydrogenase (PDH) kinase 4, were increased with increasing doses of STZ. Cardiac PDH activity displayed a dose-dependent relationship between enzyme activity and STZ concentration. Cardiac insulin-stimulated glycolytic rates were decreased by 17% in 15 mg/kg STZ high-fat fed diabetic rats compared with control rats, with no effect on cardiac contractile function. High-fat feeding in combination with a low dose of STZ induced cardiac metabolic changes that mirror the decrease in glucose metabolism and increase in fat metabolism in diabetic patients. While low doses of 15–25 mg/kg STZ induced a type 2 diabetic phenotype, higher doses more closely recapitulated type 1 diabetes, demonstrating that the severity of diabetes can be modified according to the requirements of the study.
Postchallenge responses of nitrotyrosine and TNF-alpha during 75-g oral glucose tolerance test are associated with the presence of coronary artery diseases in patients with prediabetes
Springer Science and Business Media LLC - Tập 11 - Trang 1-11 - 2012
Chih-Sheng Chu, Kun-Tai Lee, Kai-Hong Cheng, Min-Yi Lee, Hsuan-Fu Kuo, Tsung-Hsien Lin, Ho-Ming Su, Wen-Chol Voon, Sheng-Hsiung Sheu, Wen-Ter Lai
Meta-analysis has demonstrated an exponential relationship between 2-hr postchallenge hyperglycemia and coronary artery disease (CAD). Pulsatile hyperglycemia can acutely increase proinflammatory cytokines by oxidative stress. We hypothesized that postchallenge proinflammatory and nitrosative responses after 75 g oral glucose tolerance tests (75 g-OGTT) might be associated with CAD in patients without previously recognized type 2 diabetes mellitus (T2DM). Serial changes of plasma glucose (PG), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and nitrotyrosine levels were analyzed during 75 g-OGTT in 120 patients (81 male; age 62 ± 11 years) before coronary angiography. Patients were classified as normal (NGT; 42%), impaired (IGT; 34%) and diabetic (T2DM; 24%) glucose tolerance by 75 g-OGTT. Postchallenge hyperglycemia elicited TNF-α, IL-6 and nitrotyrosine levels time-dependently, and 2-hr median levels of TNF-α (7.1 versus 6.4 pg/ml; P < 0.05) and nitrotyrosine (1.01 versus 0.83 μ mol/l; P < 0.05), but not IL-6 or PG, were significantly higher in patients with CAD in either IGT or T2DM groups. After adjusting risk factors and glucose tolerance status, 2-hr nitrotyrosine in highest quartiles (OR: 3.1, P < 0.05) remained an independent predictor of CAD by logistic regression analysis. These results highlight postchallenge proinflammatory and nitrosative responses by 75 g-OGTT, rather than hyperglycemia per se, are associated with CAD in patients without previous recognized diabetes.
Association of obesity and long-term mortality in patients with acute myocardial infarction with and without diabetes mellitus: results from the MONICA/KORA myocardial infarction registry
Springer Science and Business Media LLC - Tập 14 Số 1 - 2015
Miriam Giovanna Colombo, Christa Meisinger, Ute Amann, Margit Heier, Wolfgang von Scheidt, Bernhard Kuch, Annette Peters, Inge Kirchberger
Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: a systematic review
Springer Science and Business Media LLC - Tập 22 - Trang 1-10 - 2023
Xiaolan Ouyang, Jiafu Wang, Qian Chen, Long Peng, Suhua Li, Xixiang Tang
Atrial fibrillation (AF) and heart failure (HF) frequently coexist because of their similar pathological basis. However, whether sodium-glucose cotransporter 2 inhibitor (SGLT2i), a novel class of anti-HF medication, decreases the risk of AF in HF patients remains unclear. The aim of this study was to assess the relationship between SGLT2i and AF in HF patients. A meta-analysis of randomized controlled trails evaluating the effects of SGLT2i on AF in HF patients was performed. PubMed and ClinicalTrails.gov were searched for eligible studies until 27 November 2022. The risk of bias and quality of evidence were assessed through the Cochrane tool. Pooled risk ratio of AF for SGLT2i versus placebo in eligible studies was calculated. A total of 10 eligible RCTs examining 16,579 patients were included in the analysis. AF events occurred in 4.20% (348/8292) patients treated with SGLT2i, and in 4.57% (379/8287) patients treated with placebo. Meta-analysis showed that SGLT2i did not significantly reduce the risk of AF (RR 0.92; 95% CI 0.80–1.06; p = 0.23) in HF patients when compared to placebo. Similar results remained in the subgroup analyses, regardless of the type of SGLT2i, the type of HF, and the duration of follow-up. Current evidences showed that SGLT2i may have no preventive effects on the risk of AF in patients with HF. Despite HF being one of the most common heart diseases and conferring increased risk for AF, affective prevention of AF in HF patients is still unresolved. The present meta-analysis demonstrated that SGLT2i may have no preventive effects on reducing AF in patients with HF. How to effectively prevent and early detect the occurrence of AF is worth discussing.
Tổng số: 2,027   
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 10